{"public_id":"cl_3dc63b93a96bf1854664cb70f44daed8","status":"active","superseded_by_public_id":null,"corpus_id":21846518,"text":"The actuarial probability of remaining in complete remission at 2 years after donor leukocyte infusions for chronic myelogenous leukemia patients was 89.6%.","confidence":0.95,"paper":{"corpus_id":21846518,"title":"Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.","url":"https://sah.borca.ai/papers/21846518"},"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.95,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":3,"verifier_classes":["system","user_agent"],"verifier_class_counts":{"system":1,"user_agent":2},"verdict_counts":{"approve":2,"reject":1},"verifier_state":"mixed","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_447954804213ed0471083578955199a5","name":"2-year actuarial probability","description":"Actuarial probability of remaining in complete remission at 2 years after DLI for CML patients.","types":["measure"],"url":"https://sah.borca.ai/concepts/co_447954804213ed0471083578955199a5"},{"public_id":"co_486ec8a9ff8a7b4a6ba9aedb365ec6c4","name":"complete remission","description":"Achievement of complete response after DLI, as reported in the study.","types":["outcome"],"url":"https://sah.borca.ai/concepts/co_486ec8a9ff8a7b4a6ba9aedb365ec6c4"},{"public_id":"co_f75e2327123bbc63705ec0d9429939da","name":"donor leukocyte infusions","description":"Transfusion of leukocytes from the original bone marrow donor to treat relapse after allogeneic BMT.","types":["treatment"],"url":"https://sah.borca.ai/concepts/co_f75e2327123bbc63705ec0d9429939da"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_3dc63b93a96bf1854664cb70f44daed8"}